38 results about "Adverse outcomes" patented technology

A method of identifying insights related to the occurrence of an adverse health outcome of interest, comprises extracting electronic clinical data associated with historical healthcare encounters. The method also comprises defining patient groups based upon similar data patterns present in the extracted electronic clinical data wherein the patient groups have varying likelihood for the adverse health outcome. Still further, the method comprises deriving hypothesized etiological explanations for why one or more patient groups have higher likelihood when compared to other patient groups. Optionally, the method comprises identifying clinical interventions that are intended to reduce the likelihood of the adverse outcome for certain patient groups.

The invention provides an early death risk assessment model establishing method and device based on ensemble learning. The method and device are used for assessing the death risk of an old multi-organfailure patient during hospitalization based on diagnosis and treatment data of the first day when the old multi-organ failure patient enters an intensive care unit. The method comprises the steps ofdata set construction, data processing and model construction and evaluation. The method comprises the following steps: acquiring three pieces of demographic information, five pieces of vital sign information, five laboratory examination indexes and two clinical indexes of a patient on the first day during living in an intensive care unit; inputting the data into a risk assessment device, and carrying out internal data preprocessing, feature calculation and model operation. Finally, the risk of adverse outcomes in the hospital of the patient can be predicted early, and doctors are helped to treat the patient as soon as possible.

The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma.

Provided herein are devices and methods for connecting a transcutaneous external prosthetic device to a bone, such as a bone of an amputee. The device is a two-piece transcutaneous implant device to provide reversible connection for ease of implantation, reliability, and relatively easy access for removal, while maximizing tissue ingrowth to reduce risk of infection and attendant adverse outcomes. The devices provided herein comprise a prosthetic interface and a bone anchor. A through-hole that traverses a longitudinal length of the prosthetic interface and at least a longitudinal portion of the bone anchor receives a fastener to reversibly connect the prosthetic interface to the bone anchor implanted in bone. A connector may connect to a failsafe element which, in turn, connects to an external prosthetic device.

Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and / or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and / or serious side effects from anesthesia, analgesics, and / or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.

Systems, methods, and computer-readable media are provided for patient case and care complexity characterization, and detecting matches of an individual patient's record with collections of other patients' records, based on serial, longitudinal patterns, for facilitating efficient health services utilization, implementing programs to reduce complexity, preventive medicine, and risk management in health care. In an embodiment, time series are formed by electronically representing information pertaining to successive longitudinal episodes of health services utilization and the circumstances in which the episodes were incurred; calculating time-series K-nearest-neighbor clusters and distances for each combination; determining the cluster to which a given candidate patient complexity record is nearest, and prescribing one or more interventions specific to the plurality of hazards that are characteristic of trajectories that are members of that cluster, or that are deemed to be relevant to mitigating those hazards, thereby preventing the adverse outcomes and subsequent excess utilization that are prevalent in that cluster.

In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer.

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.

Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and / or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and / or serious side effects from anesthesia, analgesics, and / or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.

A method and system for computing a relative score indicative of an individual infant's feeding performance based, at least in part, upon a comparison of one or more feeding factor measurements of the individual infant with a corresponding database metric that is derived from a population-based sample of infants, where the comparison optionally provides a statistical association between normative metric values and adverse outcomes recorded for the same population-based sample and, thereby, a means for assessing the tested infant's risk for said adverse outcomes.

A method and system for computing a relative score indicative of an individual infant's feeding performance based, at least in part, upon a comparison of one or more feeding factor measurements of the individual infant with a corresponding databased metric that is derived from a population-based sample of infants, where the comparison optionally provides a statistical association between normative metric values and adverse outcomes recorded for the same population-based sample and, thereby, a means for assessing the tested infant's risk for said adverse outcomes.

A quantitative measure of emergency department (“ED”) crowding and busyness is provided to ED staff and physicians substantially in real time. Further, the present invention enhances patient safety and improves quality of care by alerting ED personnel to of crowding, who are able to prevent adverse outcomes typically caused by ED crowding.

The invention relates to a composition for relieving alcoholism and protecting liver. The composition is prepared from the following raw materials in parts by weight: 2-3 parts of L-cysteine, 3-6 parts of taurine, 8-12 parts of glycine, 10-20 parts of curcumin, 10-20 parts of silymarin and 30-60 parts of quercetin. An in-vitro alcohol dehydrogenase (ADH) activity test and an oxygen radical absorbance capacity (ORAC) test prove that the composition disclosed by the invention has the capacity of instantly and effectively improving the activity of alcohol dehydrogenase (ADH) and accelerating ethanol metabolism, and can be used for efficiently clearing free radicals, reducing oxidative damages caused by ethanol and simultaneously preventing adverse outcomes including drunkenness, dizziness, alcoholic liver injuries and the like caused by one-time heavy drinking and long-term drinking. The composition can be prepared into foods and health foods with functions of relieving alcoholism and protecting liver, and can be used as an auxiliary product and the like for instantly relieving alcoholism and protecting the liver for a long time.

Transcriptomics data from tumor tissue of patients diagnosed with metastatic breast cancer are clustered and associated with overall survival of the patients. A subset of genes from one of the clusterassociated with poor outcome are used to generate a survival prediction model predicting a survival time based on expression levels of a plurality of genes. Using such generated survival prediction model, a survival time of a patient diagnosed with metastatic breast cancer can be predicted and a treatment regimen can be updated or generated based on the survival time.

Provided herein are devices and methods for connecting a transcutaneous external prosthetic device to a bone, such as a bone of an amputee. The device is a two-piece transcutaneous implant device to provide reversible connection for ease of implantation, reliability, and relatively easy access for removal, while maximizing tissue ingrowth to reduce risk of infection and attendant adverse outcomes. The devices provided herein comprise a prosthetic interface and a bone anchor. A through-hole that traverses a longitudinal length of the prosthetic interface and at least a longitudinal portion of the bone anchor receives a fastener to reversibly connect the prosthetic interface to the bone anchor implanted in bone. A connector may connect to a failsafe element which, in turn, connects to an external prosthetic device.

The disclosed apparatus, systems and methods relate to predicting, screening, and monitoring for mortality and other negative patient outcomes. Systems and methods may include receiving one or more signals from one or more sensing devices; processing the one or more signals to extract one or more features from the one or more signals; analyzing the one or more features to determine one or more values for each of the one or more features; comparing at least one of the one or more values or a measure based on at least one of the one or more values to a threshold; determining a presence, absence, or likelihood of the subsequent mortality, falls or extended hospital stays for a patient based on the comparison; and outputting an indication of the presence, absence, or likelihood of the subsequent development of poor outcomes or death for the patient.

A computer-based system to determine whether patients should be treated as inpatients or outpatients. The invention makes personalized predictions about the risk and timing of adverse outcomes for the patient, and further assesses how this risk and timing may vary if the patients are treated as inpatients or outpatients. This information informs how patients are assigned to an appropriate therapy. The invention includes logic relevant to predicting patient risk, decoupling patient risk into components inherent to the patient as well as additions / subtractions associated with the choice of treatment, and predicting the timing of adverse outcomes given censored data. The invention can be extended to use in a broad range of other application domains (e.g., matching learners to courses either offered in-classroom or online for education).

A method of determining a therapeutic regimen in a patient with cancer comprising determining in a sample from the patient the tumor mutation burden (TMB) and loss of heterozygosity (LOH), wherein high TMB in combination with no LOH is indicative of a positive outcome when treated with a checkpoint inhibitor and high TMB with LOH is indicative of a poor outcome, is provided herein.

The invention discloses a pregnant woman nutrition bag suitable for gestational diabetes mellitus and a preparation method thereof. The pregnant woman nutrition bag comprises the following raw materials: maltodextrin, resistant starch, whey protein concentrate and the like. The preparation method comprises the following steps: proportioning, homogenizing and packaging. The specific full-nutrition formula special medical food designed for gestational diabetes mellitus patients can effectively improve the malnutrition state of pregnant women, reduce the blood sugar level and reduce the incidence rate of gestation complications and adverse outcomes.

The invention discloses a Y-type joint pouring technology which is implemented by a primary pouring system and an auxiliary system, wherein the primary pouring system comprises a casting head, a feeding area, a feeding channel, a product wax pattern and a semi-closed space; a feeding sprue is formed in the top outer wall of the feeding area; the casting head is welded on the inner wall of the feeding sprue; the casting head and the feeding sprue are arranged at main hot spots of a casting by a step of arranging the feeding sprue and the casting head are the main hot spots of the casting according to the casting structure; continuous feeding is facilitated in a cooling process; through vertical pouring and under the pressure formed by the weight of molten steel, enough feeding ability is guaranteed for the part cooled earlier, based on a rule that thin walls are cooled earlier and the thick and big walls are supplemented. According to the technology disclosed by the invention, enough feeding ability is guaranteed for the part cooled earlier, thus, heat crack caused by stress concentration in molten steel cooling resulting from non-uniform wall thickness can be prevented, air holes and roughness caused by overheating as well as consequent adverse outcomes are avoided, and the requirements on the product performance are completely met.

The usage of compounds that improve fetal and neonatal outcome of preterm birth is described. These compounds are scavengers of ROS, their precursors, and agents that induce production of the scavengers. Examples of these compounds are glutathione, NAC, antioxidants, and spin trapping compounds. These compounds improve fetal outcome by inhibiting a fetal inflammatory process that may affect the fetus independently of prematurity. This fetal inflammatory response is characterized by increased cytokine and matrix metalloproteases (MMP) levels both in the mother and fetus and may be modulated by ROS at different levels. Targeting ROS formation with compounds such as specific antioxidants, glutathione or spin trapping compounds, their precursors, and / or agents which induce their production will suppress both the direct effects of ROS and its indirect effects through cytokines and MMPs already circulating in the system. This therapeutical intervention would limit the pathophysiologoical chain of events that ultimately leads to PPROM, preterm birth and / or adverse fetal and neonatal outcome.

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.

Disclosed herein are compositions, kits and methods for determining the concentration of fluid-phase MASP-2 / C1-INH complex in a biological fluid, such as a biological fluid obtained from a subject infected with SARS-CoV-2. Also disclosed are methods of using said compositions, methods and kits for detection of MASP-2 / C1-INH complex to determine the status of lectin pathway activation in a mammalian subject and thereby assess the risk of a subject that is or has been infected with SARS-CoV-2 for developing COVID-19-related ARDS or other poor outcome, or determine the need for treatment or efficacy of treatment of a subject in need thereof with a complement inhibitor such as a MASP-2 inhibitory agent.